tirzepatide i danmark Tirzepatide Tops Semaglutide for Weight Loss in Head-to-Head Trial, Eli Lilly Says Lilly to launch its obesity
Description
Since its FDA approval for type 2 diabetes in 2022, tirzepatide has quickly gained attention as a powerful new option for weight management
However, early studies in patients with type 2 diabetes suggested impaired GIP responsiveness, leading many researchers to conclude that targeting GIP would be therapeutically futile [5]
It is probably not likely that a doctor will prescribe Tirzepatide to people who do not have type 2 diabetes or weight-related issues
Researchers then randomized 670 participants to take either tirzepatide or placebo for another 52 weeks (double blinded)
A relatively new treatment termed Tirzepatide has shown promise in helping patients control their diabetes and reach their weight loss objectives
